Supplemental Data from XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus

Table S1: IC50 values of Topo IIa inhibitors (idarubicin, etoposide, mitoxantrone, daunorubicin) and selinexor at 48hrs as measured by WST-1 assay for AML cell lines MV4-11 and MOLM-13. Table S2: Combinatorial Index (CI) values of concomitant treatment of selinexor with Topo IIa inhibitors (idarubicin and daunorubicin) in AML cell lines MV4-11 and MOLM-13. Table S3: Combinatorial Index (CI) values of concomitant treatment of selinexor with Topo IIa inhibitors (idarubicin and daunorbicin) in AML patient blasts. Table S4: Combinatorial Index (CI) values of concomitant treatment of selinexor with individual Topo IIa inhibitors (etoposide, mitoxantrone) in AML cell lines MV4-11 and MOLM-13. Table S1: IC50 values of Topo IIα inhibitors and selinexor in AML cell lines Table S2: Combinatorial Index (CI) values of selinexor with idarubicin and daunorubicin in AML cell lines Table S3: Combinatorial Index (CI) values of selinexor with idarubicin/daunorubicin in AML patient cells Table S4: Combinatorial Index (CI) values of selinexor with Topo IIα inhibitors (etoposide and mitoxantrone) with selinexor in AML cell lines</p